Expert Interview
A Second View: Looking into the recent decision by Pfizer to remove its sickle cell disease medication OXBRYTA (voxelotor) from the market.
Ticker(s): PFE, FULCInstitution: Boston Medical Center
- Associate professor of Pediatrics at Boston University Chobanian & Avedisian School of Medicine
- Hematologist/Oncologist who sees 200 patients with Sickle Cell Disease
- Research interests focus on quality of care in sickle cell disease, and transition from pediatric to adult care.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
